Migraine Therapeutics - Pipeline Assessment and Market Forecasts to 2016

Migraine Therapeutics - Pipeline Assessment and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Migraine - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global migraine market. The report identifies the key trends shaping and driving the global migraine market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global migraine sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key driver and challenges of the global migraine market. Its scope includes:

• Annualized global migraine market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include 5-HT1D agonist, 5-HT1 agonist, AMPA/kainate receptor antagonist, Neuro transmitter system receptor, bacterial Neurotoxin (muscle relaxant), 5-HT targetor, calcitonin gene related peptide (CGRP) targetors, GABA transaminase inhibitors, nitric oxide inhibitors, prostaglandin synthesis inhibitor, opioid receptor agonist, antiemetic and gastroprokinetic agents, anti-inflammatory and immunosuppressant, and cyclooxygenase-2 (COX-2) inhibitors.
• Analysis of the current and future market competition in the global migraine market. Key market players covered are GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Inc., Pozen, Inc., Eisai Co., Ltd., Johnson & Johnson, Inc., NuPathe Inc., and Abbott Laboratories.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with migraine therapeutics.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global migraine market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global migraine market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global migraine market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 MIGRAINE THERAPEUTICS: MARKET CHARACTERIZATION

2.1 Market Overview
2.2 Overview on Accessibility of Various Migraine Treatments in the Market
2.3 Migraine Market Size
2.4 Migraine Market Forecast and CAGR
2.5 Drivers and Barriers for the Migraine Market
  2.5.1 Drivers for the Migraine Market
  2.5.2 Barriers for the Migraine Market
2.6 Opportunity and Unmet Need
2.7 Key Takeaway

3 MIGRAINE THERAPEUTICS: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in Migraine Market
  3.3.1 ZOMIG (ZOMIG, ZOMIG-ZMT)
3.4 Maxalt
  3.4.2 Frova
  3.4.3 Relpax
  3.4.4 Axert/Almogran
  3.4.5 Amerge
3.5 Key Takeaway

4 MIGRAINE THERAPEUTICS: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 Migraine Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
  4.4.1 Lasmiditan (COL-144; LY573144)
  4.4.2 BOTOX
  4.4.3 Tezampanel
  4.4.4 Telcagepant
4.5 Migraine Therapeutic Market – Clinical Pipeline by Mechanism of Action
4.6 Migraine Pipeline – Pipeline by Clinical Phases of Development
  4.6.1 Migraine Therapeutics – Phase III Clinical Pipeline
  4.6.2 Migraine Therapeutics – Phase II Clinical Pipeline
  4.6.3 Migraine Therapeutics – Phase I Clinical Pipeline
  4.6.4 Migraine Therapeutics – Preclinical Pipeline
  4.6.5 Migraine Therapeutics – Discovery Pipeline
4.7 Discontinued/ Suspended Drugs for Migraine
4.8 Key Takeaway

5 MIGRAINE THERAPEUTICS: IMPLICATIONS FOR FUTURE MARKET COMPETITION


6 MIGRAINE THERAPEUTICS: FUTURE PLAYERS IN THE MIGRAINE MARKET

6.1 Introduction
6.2 CoLucid Pharmaceuticals, Inc.
  6.2.1 Company Overview
  6.2.2 Major Products & Services
  6.2.3 CNS Pipeline Overview
6.3 GlaxoSmithKline
  6.3.1 Company Overview
  6.3.2 Business Description
  6.3.3 CNS Pipeline Overview
6.4 Eli Lilly and Company
  6.4.1 Company Overview
  6.4.2 Business Description
  6.4.3 CNS Pipeline Overview
6.5 Merck & Co Inc
  6.5.1 Company Overview
  6.5.2 Business Description
  6.5.3 CNS Pipeline Overview
6.6 POZEN Inc.
  6.6.1 Overview
  6.6.2 Business Description
  6.6.3 CNS Pipeline Overview

7 MIGRAINE THERAPEUTICS: APPENDIX

7.1 Definitions
7.2 Abbreviations
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources 48

LIST OF TABLES

Table 1: Migraine Therapeutics, Global, Market Revenue, 2001–2009
Table 2: Migraine Therapeutics, Global, Market Forecast, 2009–2016
Table 3: Major Marketed Products Analysis in Migraine Market, 2010
Table 4: Migraine Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 5: Migraine Therapeutics – Phase III Clinical Pipeline, 2010
Table 6: Migraine Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: Migraine Therapeutics – Phase I Clinical Pipeline, 2010
Table 8: Migraine Therapeutics – Preclinical Pipeline, 2010
Table 9: Migraine Therapeutics – Discovery Pipeline, 2010
Table 10: List of Discontinued/Suspended Drugs for Migraine, 2010
Table 11: CoLucid Pharmaceuticals – CNS Pipeline, 2010
Table 12: GlaxoSmithKline – CNS Pipeline, 2010
Table 13: Eli Lilly & Company – CNS Pipeline, 2010
Table 14: Merck & Co Inc – CNS Pipeline, 2010
Table 15: Pozen Inc – CNS Pipeline, 2010

LIST OF FIGURES

Figure 1: Migraine Therapeutics, Global, Market Revenue, 2001–2009
Figure 2: Migraine Therapeutics, Global, Market Forecast, 2009–2016
Figure 3: Opportunity and Unmet Need in the Migraine Market, 2010
Figure 4: Strategic Competitor Assessment of the Marketed Products for Migraine, 2010
Figure 5: Technology Trends Analytic Framework of the Migraine Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Migraine Pipeline – Description, 2010
Figure 7: Migraine Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Migraine Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in Migraine Market, 2010
Figure 10: Migraine Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model Skip to top